Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Butetamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.48 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butamirate SCHEMBL636120 | 0.93 | KDM4E (0.88) | KDM4EMAPTLMNACYP1A2CYP2D6 | |
| Butetamate SCHEMBL1643343 | 0.88 | KDM4E (0.84) | KDM4ELMNACYP1A2CYP2D6CYP3A4 | |
| Butetamate SCHEMBL8721011 | 0.84 | KDM4E (0.78) | KDM4ELMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL9588277 | 0.84 | KDM4E (0.78) | KDM4ELMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL9588408 | 0.82 | KDM4E (0.76) | KDM4ELMNACYP1A2CYP2D6CYP3A4 | |
| Oxalic Acid SCHEMBL9589927 | 0.80 | KDM4E (0.72) | KDM4ELMNACYP1A2CYP2D6CYP3A4 | |
| Butamirate SCHEMBL668881 | 0.80 | KDM4E (1.00) | KDM4ELMNACYP1A2CYP2D6CYP3A4 | |
| Butetamate SCHEMBL7339744 | 0.79 | KDM4E (0.70) | KDM4ELMNACYP1A2CYP2D6CYP3A4 | |
| SCHEMBL9325583 | 0.78 | KDM4E (0.64) | KDM4EMAPTLMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL26100 | 0.76 | CYP3A4 (0.70) | KDM4ELMNACYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026097641-A1 | TROPHOBLAST-FREE ONE-STEP METHOD FOR CULTURING TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF | 毕诺济(上海)生物技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2025098984-A1 | COMPOSITE FILM OF POLYETHERSULFONE AND OF PARTICLES OF ZIRCONIUM OXIDE OF FORMULA ZRO2, AND USE THEREOF AS ION-CONDUCTING MEMBRANE | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2025-05-15 | — | — | WO | disclosed |
| US-20210332392-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR SCANDIUM SEPARATION FROM RARE EARTH CONTAINING MATERIAL | U.S. DEPARTMENT OF ENERGY | 2021-10-28 | — | — | US | disclosed |
| WO-2021217148-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR SCANDIUM SEPARATION FROM RARE EARTH CONTAINING MATERIAL | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-1993741-B1 | INLINE APPLICATION OF COATINGS | COOK MEDICAL TECHNOLOGIES LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8523937-B2 | Controlled drug delivery using a zein layer modified with levulinic acid | COOK MEDICAL TECHNOLOGIES LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8303648-B2 | Artificial venous valve containing therapeutic agent | COOK MEDICAL TECHNOLOGIES LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8092819-B2 | Implantable medical device coated with a bioactive agent | Cook Medical Technologies LLC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8024851-B2 | Method of producing a radially expandable prosthesis | COOK MEDICAL TECHNOLOGIES LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-7914841-B2 | Inline application of coatings | COOK MEDICAL TECHNOLOGIES LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070196423-A1 | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent | MED INSTITUTE, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070182055-A1 | Inline application of coatings | COOK INCORPORATED (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070043423-A1 | Intraluminal device with a hollow structure | MED INSTITUTE INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2005082393-A1 | STABILIZED FEVERFEW FORMULATIONS | SOFT GEL TECHNOLOGIES, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050186269-A1 | Stabilized feverfew formulations | THE CIT GROUP/CREDIT FINANCE, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-0805680-A2 | COMBINATIONAL DRUGS FOR TREATING MIGRAINE AND OTHER ILLNESSES, COMPRISING SESQUITERPENE LACTONES AND B-COMPLEX VITAMINS | Ashbury Research Corporation (CA) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022774-A2 | COMBINATIONAL DRUGS FOR TREATING MIGRAINE AND OTHER ILLNESSES, COMPRISING SESQUITERPENE LACTONES AND B-COMPLEX VITAMINS | ASHBURY RESEARCH CORPORATION (CA) | 1996-08-01 | — | — | WO | disclosed |
| EP-0098041-B1 | SESQUITERPENE LACTONES, EXTRACTS CONTAINING THEM, THEIR PREPARATION AND PHARMACEUTICAL USE | R.P. SCHERER CORPORATION (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4758433-A | Oil extract of Tanacetum parthenium for treating migraine | R. P. SCHERER CORP. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0098041-A2 | Sesquiterpene lactones, extracts containing them, their preparation and pharmaceutical use | R.P. SCHERER CORPORATION (US) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050186269-A1 | Stabilized feverfew formulations | HAMP, S100P, PYGB | MEN1 124/4885SLC6A2 2856/4885OPRM1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.